Amarin Announces 30th Patent for Vascepa(R)

Amarin Announces 30th Patent for Vascepa(R)

Recent Allowances Continue to Broaden Coverage

BEDMINSTER, N.J., and DUBLIN, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that it now has 30 patents issued or allowed by the
United States Patent and Trademark Office (USPTO) related to its flagship
product, Vascepa^® (icosapent ethyl) capsules.

Amarin recently received Notices of Allowance for U.S. Patent Application
Serial Numbers 13/777,398, 13/768,897, and 13/768,869, each titled "Stable
Pharmaceutical Composition and Methods of Using Same." The scope of coverage
related to Vascepa represented by these applications is the broadest allowed
to date.

"With 30 patents issued and allowed and over 30 additional applications
pending in the United States, Amarin now has one of the most extensive, and
expanding, patent portfolios covering a product in the industry," stated
Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "Amarin is
pleased that the USPTO continues to recognize the novel characteristics of
Vascepa. The continued issuance of a variety of patents covering Vascepa is
emblematic of the success achieved at Amarin toward its goal of protecting the
commercial potential of Vascepa to beyond 2030 through patent protection. In
addition, Amarin's Vascepa is also protected by trade secrets and existing
manufacturing barriers to entry, along with anticipated three- or five-year
regulatory exclusivity in the United States."

Amarin is also making significant progress with its patent applications
related to Vascepa in multiple jurisdictions outside the United States,
including the May 2013 patent grant by the European Patent Office covering the
use of Vascepa based on the results from the MARINE trial.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit For more information about Amarin visit

Forward-looking statements

This press release contains forward-looking statements, including statements
about whether the subject patents would be issued and adequately protect
Vascepa against competition, Amarin's plan to protect the commercial potential
of Vascepa, and the future status of pending patent applications. These
forward-looking statements are not promises or guarantees and involve
substantial risks and uncertainties. Among the factors that could cause actual
results to differ materially from those described or projected herein include
the following: events that could interfere with the issuance of a patent, or
once issued, the continued validity or enforceability of a patent; Amarin's
ability generally to maintain adequate patent protection and successfully
enforce patent claims against third parties; commercializing Vascepa without
violating the intellectual property rights of others; and uncertainties
associated generally with research and development, clinical trials and
related regulatory approvals. A further list and description of these risks,
uncertainties and other risks associated with an investment in Amarin can be
found in Amarin's filings with the U.S. Securities and Exchange Commission,
including its most recent Quarterly Report on Form 10-Q. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and
the public using our company website (, our investor
relations website (, including
but not limited to investor presentations and investor FAQs,Securities and
Exchange Commissionfilings, press releases, public conference calls and
webcasts. The information that we post on these channels and websites could be
deemed to be material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information that we post
on these channels, including our investor relations website, on a regular
basis. This list of channels may be updated from time to time on our investor
relations website and may include social media channels. The contents of our
website or these channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933.

CONTACT: Amarin contact information:
         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315

company logo
Press spacebar to pause and continue. Press esc to stop.